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MTA3 and the Mi-2/NuRD Complex Regulate Cell
Fate during B Lymphocyte Differentiation
immunity relies on the proper differentiation of B lym-
phocytes into antibody-secreting cells (Bishop et al.,
2003). Central to this process is the germinal center
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permutation. Following selection of high-affinity anti-3 Winship Cancer Institute
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ulators of the germinal center B lymphocyte and plasma
cell transcriptional programs are the transcriptional re-
pressors BCL-6 and Blimp-1 (Calame et al., 2003). Con-Summary
siderable effort has been devoted to determination of
the transcriptional programs downstream of these twoThe transcriptional repressor BCL-6 regulates B lym-
repressors. In the germinal center B lymphocyte, BCL-6phocyte cell fate during the germinal center reaction
activity is required for repression of markers, includingby preventing terminal differentiation of B lympho-
Blimp-1, the cytokine CCL3, Syndecan 1, and the tran-cytes into plasma cells until appropriate signals are
scription factor XBP1, of the plasma cell transcriptionalreceived. Here, we report a cofactor, MTA3, a cell type-
program (Shaffer et al., 2000). In contrast, Blimp-1 activ-specific subunit of the corepressor complex Mi-2/
ity is required to stably repress markers, including CIITA,NuRD, for BCL-6-dependent cell fate determination.
BLNK, Ig, and SYK, of the germinal center B cell tran-MTA3 is expressed in the same pattern in germinal
scriptional program (Shaffer et al., 2002a). Recent workcenters as BCL-6. BCL-6 physically interacts with
has demonstrated that Blimp-1 facilitates transcrip-Mi-2/NuRD and this interaction is sensitive to BCL-6
tional repression through recruitment of the histoneacetylation status. Depletion of MTA3 by RNAi impairs
methyltransferase G9a (Gyory et al., 2004). BCL-6, inBCL-6-dependent repression and alters the cell-spe-
contrast, represses transcription through the recruit-cific transcriptional pattern characteristic of the B lym-
ment of corepressors including NCoR (Huynh and Bard-phocyte. Remarkably, exogenous expression of BCL-6
well, 1998), SMRT (Wong and Privalsky, 1998), andin a plasma cell line leads, in an MTA3-dependent man-
BCoR (Huynh et al., 2000). While much progress hasner, to repression of plasma cell-specific transcripts,
been made in the definition of an HDAC-dependent re-reactivation of the B cell transcriptional program, ex-
pression mechanism utilized by BCL-6, in the contextpression of B lymphocyte cell surface markers, and
of the germinal center B lymphocyte, the repressionreprogramming of cell fate.
mechanism of this key regulator has not been fully de-
fined.Introduction
The Mi-2/NuRD complex represents an abundant co-
repressor present in diverse cell types (Bowen et al.,In multicellular organisms, the essential biological pro-
2004). This complex is heterogenous in subunit compo-cesses of development and differentiation result in the
sition, leading to the prediction that subunit heterogene-creation of multiple cell types, each with its own unique
ity produces functionally distinct corepressor com-
pattern of gene expression. The portion of the genome
plexes (Bowen et al., 2004). MTA3, a cell type-specific
active in any given cell type results from the balance of
subunit of the Mi-2/NuRD complex, has been recently
two opposing activities, transcriptional activation and identified as a component of a genetic pathway regulat-
transcriptional repression. For many differentiated cell ing differentiation in mammary epithelial cells (Fujita et
types, the transcriptional program is under the control al., 2003). In this context, MTA3 is required for recruit-
of master regulatory factors. A classic example of such ment of Mi-2/NuRD to at least one promoter, resulting
a factor is MyoD, a basic helix-loop-helix transcription in HDAC-dependent transcriptional repression (Fujita et
factor with the capacity to direct the muscle cell-specific al., 2003). The role(s) of MTA3 or the Mi-2/NuRD complex
transcriptional program (Weintraub et al., 1991). While in general as a regulator of cell fate determination in
master regulatory factors are frequently necessary for other contexts remain unknown. Whether specific sub-
the establishment of cell type-specific transcription, it is units of Mi-2/NuRD, in addition to MTA3, act to provide
clear that in most cases eukaryotic transcription factors unique functionality in cell type-specific transcriptional
utilize cofactors, termed coactivators and corepressors, programs has not been determined.
to facilitate modulation of gene expression (Jaskelioff In this work, we report a novel and intriguing cell type-
and Peterson, 2003). specific function of MTA3 and the Mi-2/NuRD complex.
Transcriptional regulation plays an integral role in the MTA3 is expressed in a biologically distinct subset of
control of development and differentiation in the verte- lymphocytes: germinal center B cells. As the pattern of
brate immune system. The development of acquired MTA3 expression mirrored the expression pattern of the
master regulator, BCL-6, of B cell differentiation, the
interaction between MTA3 and BCL-6 was examined.*Correspondence: pwade@emory.edu
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that functions during lymphoid development (Niu, 2002;
Ye et al., 1993), revealed that these two transcriptional
regulators were coexpressed in the same population of
germinal center B lymphocytes (Figures 1D–1F).
The precise coexpression of MTA3 and BCL-6 sug-
gested a functional role in the biology of the germinal
center B lymphocyte. To investigate this further, immu-
noblot analysis of whole-cell extracts from human and
mouse cell lines revealed high-level expression of both
MTA3 and BCL-6 in cell lines representative of B lym-
phocytes; the cell lines include Raji (Epstein et al., 1966),
RJ2.2.5 (Accolla, 1983), BJAB (Zech et al., 1976), Ramos
(Klein et al., 1975), HS Sultan (Harris, 1974), and BCL-1
(Slavin and Strober, 1978) (Figure 1G). In contrast, the
plasmacytoma lines H929 (Gazdar et al., 1986) and
U266B1 (Nilsson et al., 1970) and the myeloma cell line
P3U1 (Unkeless, 1979) exhibited little to no expression
of these two proteins, suggesting that these cell lines
could be utilized to investigate physical and functional
interactions between the repressor BCL-6 and the core-
pressor Mi-2/NuRD.
MTA3 Associates with BCL-6
Exogenous expression of BCL-6 and MTA3 with epitope
Figure 1. MTA3 and BCL-6 Are Expressed in Germinal Center B tags in 293T cells followed by immunoprecipitation re-
Lymphocytes
vealed that the two proteins interacted, either directly
(A)–(C) display a section of lymph node with reactive follicular hyper-
or indirectly (Figure 2A). To authenticate this observationplasia that was immunostained (23) with anti-MTA3 antibodies (mag-
in a more physiologically relevant context, coprecipita-nifications: A, 40; B, 100; C, 400). Following staining with sec-
tion experiments were performed in whole-cell extractsondary reagents, bound antibodies were detected by a standard
DAB reaction. In a separate experiment, a section of chronically of the B cell line RJ2.2.5. Immunoprecipitation of endog-
inflamed tonsil was double-stained with anti-MTA3 (D, red) and anti- enous BCL-6 led to coprecipitation of MTA3 as well as
Bcl-6 antibodies (E, green). The merged image is shown in (F). All three other subunits of Mi-2/NuRD: MBD3, HDAC1, and
nuclei were labeled with To-pro-3 iodide (D–F, blue).
Mi-2 (Figure 2B). Converse experiments demonstrated(G) Immunoblot analysis of whole-cell extracts from the indicated
that BCL-6 coprecipitated with four different subunitshuman and mouse cell lines was performed with antibodies against
of the Mi-2/NuRD complex, including MTA3 (Figure 2C).the indicated proteins.
We concluded from these experiments that BCL-6 forms
a stable interaction with the MTA3-containing version
of the Mi-2/NuRD corepressor complex. Interactions be-MTA3 physically associated with BCL-6 in extracts from
B lymphocyte cell lines, and depletion of MTA3 from tween BCL-6 and other corepressors have been re-
ported (Dhordain et al., 1997; Huynh and Bardwell, 1998;these cells by RNAi led to concomitant alterations in
their cell type-specific transcriptional program. The in- Huynh et al., 2000; Wong and Privalsky, 1998). However,
we failed to detect robust expression of two of theseteraction of BCL-6 and MTA3 was regulated by acetyla-
tion of BCL-6 itself, a modification known to affect the molecules, NCoR and SMRT, in extracts prepared from
Raji and RJ2.2.5 (Figure 2D), indicating that these mole-ability of BCL-6 to repress transcription (Bereshchenko
et al., 2002). Moreover, exogenous expression of BCL-6 cules are expressed at low levels in the immortalized
B cell lines utilized in this work.in a plasma cell line led to reprogramming of cell fate
toward that of a B lymphocyte in an MTA3-dependent To dissect the interaction between MTA3 and BCL-6,
protein-protein interaction assays were employed. Sev-fashion. Together, these data suggest a prominent role
for MTA3 in B cell fate determination. eral regions of BCL-6 were produced in recombinant
bacteria as GST fusions. The purified GST-BCL-6 deriva-
tives were subsequently incubated with nuclear extractsResults
from Raji cells. In this assay, robust interaction of BCL-6
with MTA3 and the Mi-2/NuRD complex was observedMTA3 Expression in Lymphoid Tissue
In an immunohistochemical survey of MTA3 expression using the central region of the BCL-6 protein (Figure
3A). Other regions of BCL-6, including the BTB-POZin breast cancer specimens (Fujita et al., 2003), a slide
containing a lymph node was encountered. Closer ex- domain, failed to interact productively with MTA3 and
the Mi-2/NuRD complex. This result was somewhat sur-amination of this and other slides containing secondary
lymphoid tissues revealed high-level expression of prising as the interaction between BCL-6 and other core-
pressors, including NCoR (Huynh and Bardwell, 1998),MTA3 at germinal centers. Figure 1 (panels A–C) depicts
a human lymph node stained for MTA3. High-level ex- SMRT (Huynh and Bardwell, 1998; Wong and Privalsky,
1998), and BCoR (Huynh et al., 2000), is mediated by thepression is largely restricted to the germinal center. Im-
munofluorescence analysis of frozen sections of human BTB-POZ domain. To determine whether the interaction
between BCL-6 and the Mi-2/NuRD complex involvedtonsil with antibodies to MTA3 and BCL-6, a repressor
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demonstrating a direct interaction between the C termi-
nus of MTA3 and the central region of BCL-6.
The MTA3 Mi-2/NuRD Complex Directs
Repression by the BCL-6 Central Repression Domain
The coordinate expression and physical interaction of
BCL-6 with MTA3 suggested a functional interaction. To
investigate the potential role of MTA3 in transcriptional
repression by BCL-6, we employed a Gal4 tethering
assay. BCL-6 fused in-frame to the Gal4 DNA binding
domain was cotransfected into HeLa cells with a consti-
tutively expressing luciferase reporter construct con-
taining Gal4 binding sites (Fujita et al., 2003). HeLa cells
were utilized because they are readily transfected and
they express endogenous MTA3 at high levels (Fujita et
al., 2003). Gal4-BCL-6 repressed transcription from the
reporter in a dose-dependent manner (Figure 3C). As
other corepressors have been demonstrated to interact
with BCL-6 and mediate transcriptional repression by
interaction with the BTB-POZ domain (Dhordain et al.,
1997; Huynh and Bardwell, 1998; Huynh et al., 2000;
Wong and Privalsky, 1998), specific regions of BCL-6
were tested in this assay for repressive activity. As ex-
pected, the BTB-POZ domain when fused to the Gal4
DNA binding domain repressed transcription from the
reporter in a dose-dependent manner. However, a mu-
tant version of BCL-6 lacking the BTB-POZ domain (con-
struct 2, Figure 3C) also functioned as a transcriptional
repressor in this assay. Further deletion mutations
mapped the minimal region sufficient for transcriptional
repression to the central 367 amino acids (construct 5,
Figure 3C). These data suggested that BCL-6 has two
independent transcriptional repression domains: the
BTB-POZ domain and the central region.
To investigate the requirement for MTA3 function in
transcriptional repression driven by BCL-6 in the Gal4
tethering assay, RNA interference was utilized. In the
Gal4 tethering assay, transcriptional repression by full-
length BCL-6 was reduced by MTA3 siRNA treatment
(Figure 3D). Repression driven by the central region of
BCL-6 was affected to a somewhat greater extent by
MTA3 depletion. We concluded that MTA3 contributes
Figure 2. MTA3 Physically Associates with BCL-6 in B Cells
to transcriptional repression by Gal4-BCL-6 through in-
(A) Epitope-tagged versions of BCL-6 and MTA3 were expressed
teraction with a transcriptional repression domain in thein 293T cells and immunoprecipitations were performed with the
central region of BCL-6.indicated epitope antibodies. Detection of BCL-6 and MTA3 by their
respective epitope tags is indicated on the figure.
(B) The indicated antibodies to Mi-2/NuRD subunits were used in Acetylation of BCL-6 Alters Its Interaction
immunoprecipitations from RJ2.2.5 extracts. BCL-6 was detected with MTA3 and Its Ability to Repress Transcription
in the precipitates as indicated in the figure. The central region of BCL-6 is of immense interest as
(C) Immunoprecipitation of BCL-6 from RJ2.2.5 extracts was per-
Dalla-Favera and colleagues have defined in this regionformed. Mi-2/NuRD subunits were detected in the precipitates using
of the protein acetylation sites that are key regulatorsthe indicated antibodies.
(D) Whole-cell extracts from the indicated cell lines were analyzed of transcriptional repression function (Bereshchenko et
for NCoR, SMRT, MTA2, and actin by immunoblot as indicated in al., 2002). As the region defined in this work overlaps
the figure. with the acetylation sites of BCL-6 (Figure 3A), we asked
whether BCL-6 acetylation status impacted MTA3-
dependent transcriptional repression. Mutant versionsa direct interaction between BCL-6 and MTA3, protein-
protein interaction assays were performed with recom- of BCL-6 were constructed that either prevent any ace-
tylation (KKYK to KKYR mutation) or mimic constitutivebinant fragments of each protein. GST-MTA3 fusions
were prepared in recombinant bacteria, purified, and acetylation (KKYK to QQYQ) in the context of the Gal4-
BCL-6 fusion. Transcriptional repression assays weretested for interaction with a purified recombinant frag-
ment of BCL-6 containing the central region (Figure 3B). again performed in HeLa cells using the luciferase re-
porter described above (Figure 3E). Both wild-typeThe carboxy-terminal 137 amino acids of MTA3 inter-
acted specifically with the BCL-6 fragment in this assay, BCL-6 and the KKYR mutant exhibited robust transcrip-
Cell
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Figure 3. Direct Interaction between MTA3 and BCL-6 Is Regulated by Acetylation
(A) The indicated regions of BCL-6 were fused to GST and produced in recombinant bacteria. The BCL-6-GST fusions were incubated with
Ramos nuclear extracts and interacting proteins were detected by immunoblot.
(B) The indicated regions of MTA3 were produced as GST fusion proteins in recombinant bacteria. After incubation with purified recombinant
BCL-6 (the 5 mutant), interacting proteins were analyzed by immunoblot.
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tional repression activity in the tethering assay. In con- effect that was modestly enhanced by Trichostatin-A.
Importantly, the amount of BCL-6 coprecipitating withtrast, the QQYQ mutant, which mimics constitutive ace-
tylation, was unable to direct transcriptional repression MTA3 was reduced by deacetylase inhibition (Fig-
ure 3G).of the reporter.
The above results suggest that the MTA3-dependent As MTA3 is physically associated with HDAC1 and
HDAC2 in the context of the Mi-2/NuRD complex (Fujitarepression function of BCL-6 is sensitive to the acetyla-
tion status of BCL-6. As MTA3 interacts directly with et al., 2003), we asked whether depletion of endogenous
MTA3 from B lymphocyte cell lines might alter theBCL-6, in a region including the sites of acetylation, we
asked whether modification status of BCL-6 affected its steady-state levels of acetylated BCL-6. We were unable
to achieve sufficient transfection of lymphocytes withcapacity to interact with MTA3. For these experiments,
BCL-6 derivatives were expressed exogenously in HeLa siRNA, therefore we resorted to an alternative strategy.
An adenovirus was constructed to deliver a DNA con-cells that express high levels of NCoR, SMRT, and MTA3
(Figure 2D). Immunoprecipitation of BCL-6 was followed struct encoding a short hairpin RNA (shRNA) to deplete
exogenous MTA3 in lymphocyte cell lines. While lym-by immunoblot analysis to analyze coprecipitation of
NCoR, SMRT, or the MTA3-containing Mi-2/NuRD com- phocytes and plasma cells do not express high-affinity
receptors for adenovirus, they can nonetheless be in-plex. Overexpression of wild-type BCL-6 resulted in co-
precipitation of all corepressor complexes analyzed fected with high efficiency (Leon et al., 1998). Infection
with the shRNA MTA3 adenovirus but not with a control(Figure 3F). The KKYR BCL-6 mutant that cannot be
acetylated also coprecipitated all three corepressors shRNA adenovirus resulted in loss of MTA3 protein with
no apparent effect on BCL-6 abundance (Figure 3H).(Figure 3F). In contrast, the QQYQ mutant that mimics
constitutive acetylation coprecipitated NCoR and SMRT Immunoprecipitations were performed with antibodies
specific for acetyl-lysine and for BCL-6, and precipitateswith comparable efficiency to wild-type but was im-
paired in its ability to coprecipitate MTA3 and the Mi-2/ were analyzed by immunoblot for either acetyl-lysine or
BCL-6 (Figure 3H). Depletion of MTA3 led to an accumu-NuRD complex. These data support the conclusion that
association of MTA3 with the central repression domain lation of acetylated forms of BCL-6. These results sug-
gest that either the HDAC activity associated with MTA3of BCL-6 was sensitive to posttranslational modification.
In addition, these results also indicate that BCL-6 inter- may play an integral role in dynamic acetylation of BCL-6
or that association of the central repression domain ofacts productively with NCoR and SMRT and that this
interaction is not altered by modification of BCL-6. BCL-6 with MTA3 physically interferes with access of
this region to the relevant acetyltransferase, believed toIf the interaction of BCL-6 and MTA3 were modulated
by acetylation, one would predict that drug treatments be p300 (Bereshchenko et al., 2002).
resulting in accumulation of the acetylated form of en-
dogenous BCL-6 might impair its interaction with en- MTA3 Is Necessary for BCL-6-Dependent
Transcriptional Repression In Vivodogenous MTA3. Accordingly, Raji cells were cultured
in the presence of niacinamide, an inhibitor of the NAD- While the above results indicated the potential impor-
tance of MTA3 for transcriptional repression function ofdependent Sir2 class of deacetylases (Landry et al.,
2000; Luo et al., 2001), with or without Trichostatin-A, BCL-6, issues relating to cellular context and overex-
pression needed to be addressed. Adenoviral shRNAan inhibitor of class I and class II histone deacetylases
(Yoshida et al., 1990). Immunoprecipitations were sub- delivery led to depletion of MTA3 protein in Raji and
BJAB B cells (Figure 4A). As shown, analysis of relevantsequently performed with antibodies specific for acetyl-
lysine, MTA3, or rabbit IgG as a control. Precipitates transcripts from the MTA3-depleted and control cell
populations revealed that three plasma cell-specificwere analyzed by immunoblot for BCL-6. Consistent
with previous reports (Bereshchenko et al., 2002), inhibi- transcripts, Blimp-1, CCL3, and Syndecan-1, were de-
repressed following MTA3 knockdown in both cell linestion of NAD-dependent deacetylation resulted in accu-
mulation of acetylated forms of BCL-6 (Figure 3G), an (Figure 4B). Thus, MTA3 function is required for full tran-
(C) A luciferase reporter plasmid containing the thymidine kinase promoter with upstream Gal4 binding sites was cotransfected into HeLa
cells along with expression plasmids for the indicated regions of BCL-6 fused to the Gal4 DNA binding domain. Luciferase activity (normalized
to Renilla luciferase transfection control) is depicted as a function of amount of Gal4-BCL-6 fusion transfected.
(D) Luciferase reporter assays were performed in HeLa cells as described in (C). Cells were treated with buffer, siRNA specific for GFP, or
siRNA specific for MTA3. Luciferase activity (normalized to Renilla luciferase transfection control) is depicted for each condition.
(E) A luciferase reporter plasmid containing the thymidine kinase promoter with upstream Gal4 binding sites was cotransfected into HeLa
cells along with expression plasmids for the indicated BCL-6 derivatives fused to the Gal4 DNA binding domain. Luciferase activity (normalized
to Renilla luciferase transfection control) is depicted for each BCL-6 expression plasmid. The immunoblot at the left depicts expression of
the different BCL-6 derivatives.
(F) The indicated BCL-6 derivatives were expressed in HeLa cells and immunoprecipitation was performed with the FLAG antibody. The left
panel depicts input for each condition and the right panel depicts proteins precipitating with the FLAG BCL-6 derivative. Individual antibodies
used to analyze the precipitates are indicated to the right of the figure.
(G) Raji B cells were grown with either no treatment, treatment with niacinamide, or treatment with niacinamide plus Trichostatin-A as indicated.
Nuclear extracts prepared from each culture condition were immunoprecipitated with the indicated antibodies. BCL-6 abundance in the
precipitates was analyzed with the anti-BCL-6 antibody.
(H) Raji B cells were infected with either a control adenovirus expressing a control shRNA or with an adenovirus expressing an MTA3-specific
shRNA. Protein lysates from cells infected as indicated were analyzed with antibodies specific for MTA3 and BCL-6. Immunoprecipitations
were performed with either anti-acetyl-lysine or anti-BCL-6 antibodies and analyzed using BCL-6 or acetyl-lysine antibodies.
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Figure 4. Endogenous MTA3 Is Required for the Transcriptional Repression Function of Endogenous BCL-6 in B Cells
(A) Raji and BJAB cells were infected with the adenovirus expressing shRNA-MTA3 or the control shRNA adenovirus. The immunoblot depicts
MTA3, MTA2, and actin levels following infection.
(B) Transcript levels for the indicated gene products were determined by RT-PCR from uninfected, mock shRNA, and shRNA-MTA3 adenovirus-
infected cells.
scriptional repression activity of endogenous BCL-6 at Coexpression of MTA3 and BCL-6 Reprograms
Plasma Cell Fatethese three loci in multiple cell lines.
To examine in more detail the functional interaction The above observation, that coexpression of BCL-6 and
MTA3 led to repression of Blimp-1 and re-expressionof MTA3 and BCL-6 in lymphoid cells, we constructed
adenovirus vectors for transient expression of these fac- of CIITA (Figure 5B), raised the intriguing possibility that
these events might lead to reprogramming of the plasmators. Infection of H929 and U266B1 plasma cells with
adenoviruses expressing BCL-6 and/or MTA3 led to in- cell lines H929 and U266B1 to a B lymphocyte-specific
transcriptional program. Blimp-1 is necessary, but notfection of the majority of the cells in the population (data
not shown) and high-level expression of the relevant sufficient, for the differentiation of B lymphocytes into
plasma cells (Shapiro-Shelef et al., 2003) and has beenproteins (Figure 5A and data not shown). To ascertain
the role of BCL-6 and MTA3 on specific genes, the levels shown to repress expression of the class II transactiva-
tor, CIITA (Piskurich et al., 2000). CIITA is a coactivatorof transcripts of multiple loci differentially regulated in
plasma cells and B lymphocytes were analyzed. By it- required, along with several well-characterized tran-
scription factors, for the expression of MHC class IIself, MTA3 expression had no effect on any transcript
examined. Expression of BCL-6 alone led to small proteins, such as HLA-DR, characteristic of B lympho-
cytes (Boss and Jensen, 2003; Ting and Trowsdale,changes in transcript abundance from these loci. How-
ever, coexpression of both BCL-6 and MTA3 led to ro- 2002). Because four different transcriptional start sites
direct CIITA expression in a cell type-specific mannerbust repression of the set of transcripts associated with
the plasma cell-specific transcriptional program, such (Muhlethaler-Mottet et al., 1997), RT-PCR was performed
with primers differentiating between the cell type-spe-as Blimp-1, CCL3, Syndecan-1, and XBP1 (Figure 5B).
In contrast, multiple transcripts diagnostic of the B lym- cific transcription start sites to determine whether the B
cell-specific promoter was used. In fact, the transcriptsphocyte transcriptional program were significantly
upregulated; these transcripts include CIITA, BLNK, Ig, accumulating in H929 cells following coexpression of
BCL-6 and MTA3 originate at promoter III, the primaryand SYK (Figure 5B).
The requirement for MTA3 for efficient transcriptional promoter used in B lymphocytes (Figure 5E).
If coexpression of BCL-6 and MTA3 leads to repro-repression at CCL3, Syndecan-1, XBP1, and Blimp-1
could result from recruitment of MTA3 and the Mi-2/ gramming of the plasma cell transcriptional program to
a B lymphocyte pattern, the expression of cell surfaceNuRD complex to these loci, or from an indirect effect.
To differentiate between these two possibilities, chro- markers should reflect the change in cell fate. Analysis
of the H929 plasma cell line for common markers reflec-matin immunoprecipitation (ChIP) assays were per-
formed on the CCL3 locus. MTA3 was recruited in a tive of B lymphocyte cell identity following infection with
BCL-6 and/or MTA3 adenovirus revealed strikingBCL-6 dependent manner to the human CCL3 promoter
following expression of these factors in the H929 plasma changes (Figure 6A). Cell surface expression of CD19
and HLA-DR was detected following transient expres-cell line (Figure 5C). Moreover, MTA3 was present natu-
rally at the CCL3 locus in the Raji B cell line (Figure 5D). sion of BCL-6, consistent with a shift from a plasma cell
pattern to a B lymphocyte pattern. The percentage ofThese experiments suggested that BCL-6-dependent
transcriptional repression in lymphoid cells requires the cells converting was dramatically increased by coex-
pression of MTA3 (Figure 6B). CD19 expression, unlikephysical presence of the MTA3-containing Mi-2/NuRD
complex in the vicinity of the promoter. HLA-DR, is CIITA independent. Thus, the pattern of pro-
MTA3 in B Cell Development
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Figure 6. Coexpression of MTA3 and BCL-6 in H929 Cells Leads to
Reversion to a B Cell-like Transcriptional Program
(A) Flow cytometric immunophenotyping was performed after 7 days
infection with adenoviral constructs carrying BCL-6, MTA3, or con-
trol; all adenoviral constructs also carried GFP. Cells were surface
labeled with Per-CP anti-HLA-DR and APC anti-CD19 or isotype
control. Dot plots are shown for the following conditions: mock-
infected control Raji cells; mock-infected H929 cells; MTA3 adenovi-
ral-infected H929 cells; BCL-6 adenoviral-infected H929 cells; BCL-6
and MTA3 adenoviral-infected H929 cells. Gates were set based on
isotype control staining levels; at least 10,000 total events were
obtained. Analysis gates in FL-1 were placed on cells that displayed
intermediate to high GFP expression (not shown). For these cells,
fluorescence intensities in FL-3 (abscissa) and FL-4 (ordinate) are
displayed on a four-decade logarithmic scale.
(B) The percentage of HLA-DR-positive cells is plotted as a function
of the relative quantity of MTA3 adenovirus used to infect the cells
with a constant quantity of coinfected BCL-6 adenovirus. The mean
fluorescent intensities of the HLA-DR-positive populations were not
statistically different (not shown). The gating strategy employed was
identical to that employed in (A).
Figure 5. MTA3 and BCL-6 Expression in Plasma Cells Alters Their
Transcriptional Program tein expression induced in this experiment includes not
(A) Adenoviruses expressing MTA3 and/or BCL-6 were used to infect only CIITA-responsive genes but other B cell-specific
H929 cells. The immunoblot depicts expression of MTA3 and/or proteins as well. Moreover, HLA-DR and CD19 expres-
BCL-6 following adenovirus infection.
sion were reactivated in the same population of cells(B) The panel depicts RT-PCR products derived from cells treated
and expression levels of these markers were indistin-as indicated in the figure. RT-PCR from Raji and Ramos cells is
shown as a control.
(C) Chromatin immunoprecipitation was performed on H929 cells
following infection with either MTA3 adenovirus or MTA3 and BCL-6
adenoviruses. The indicated primary antibodies were used to pre- expressing BCL-6 or MTA3. RNA was extracted 5 days post-infec-
cipitate chromatin following crosslinking. PCR to detect the CCL3 tion and used for RT-PCR with CIITA isotype-specific primers. Plas-
promoter region was performed on the precipitated DNA. mid expressing dendritic cell CIITA promoter 1 DNA and cDNA from
(D) Chromatin immunoprecipitation was performed on Raji cells with Raji B cells and A431 epithelial cells treated with interferon  were
the indicated primary antibodies. PCR to detect the CCL3 promoter used as sources of templates to demonstrate CIITA promoter speci-
region was performed on the precipitated DNA. ficity of the assay. RT-PCR of the glyceraldehyde-3-phosphate de-
(E) H929 cells were infected with control or adenoviral constructs hydrogenase gene is shown as a loading control.
Cell
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Elegant functional (Dhordain et al., 1997; Huynh and
Bardwell, 1998; Wong and Privalsky, 1998) and struc-
tural data (Ahmad et al., 2003) link BCL-6 transcriptional
repression function and the BTB-POZ domain to NCoR
and SMRT. The results in this work suggest that MTA3
and the Mi-2/NuRD complex function to facilitate tran-
scriptional repression by BCL-6 through interaction with
the central region of the protein. This region of BCL-6
has been identified as an independent repression do-
main by other investigators (Dhordain et al., 1998; Zhang
et al., 2001). Importantly, the repression function of this
domain is modulated by protein modification (Beresh-
chenko et al., 2002), providing an acute means of regu-
lating the transcriptional repression function of BCL-6
in response to biological cues. In the lymphoid cell lines
utilized in this work, we failed to detect significant ex-
pression of either NCoR or SMRT (Figure 2D). We pro-
pose that utilization of MTA3 and the Mi-2/NuRD com-
plex as a corepressor for BCL-6 extends its capacity
to direct transcriptional repression. Multiple possible
scenarios could result. In cells that express both NCoR/
SMRT and MTA3, BCL-6-dependent repression could
utilize both types of corepressor complex. The possibil-Figure 7. Coexpression of MTA3 and Bcl-6 in Plasmacytoma Cells
ity of locus specificity for corepressors exists as doesInduces a Switch to a B Cell Immunophenotype
the possibility of combinatorial action. NCoR and SMRTImmunocytochemical stains were performed on H929 cells 7 days
can utilize HDAC3 to repress transcription (Li et al., 2000;after coinfection with MTA3 and Bcl-6 adenoviruses. Results are
displayed for MACS-selected CD19-negative cells and CD19-posi- Underhill et al., 2000; Urnov et al., 2000; Wang and Hieb-
tive cells at magnification 400 for all panels. After labeling with ert, 2001; Wen et al., 2000), whereas the MTA3-con-
primary antibody and detection with secondary reagents, bound taining Mi-2/NuRD complex contains HDAC1 and HDAC2
antibodies were identified by a standard DAB reaction. (Fujita et al., 2003). This capacity to recruit unique his-
tone deacetylases with potential differences in substrate
specificity might expand the capacity of a transcriptionalguishable from those in Raji. This finding suggests that
repressor such as BCL-6 to effectively silence tran-once a critical level of BCL-6/MTA3 is attained, resetting
scription.of the transcriptional program proceeds.
The involvement of MTA3 in the B lymphocyte tran-To examine whether additional alterations in protein
scriptional program supports the model (Bowen et al.,
expression were evident in H929 cells following transient
2004) that MTA3 represents a cell type-specific compo-
expression of MTA3 and BCL-6, the CD19-positive and
nent of the well-described transcriptional corepressor,
-negative populations were separated (Abts et al., 1989).
Mi-2/NuRD. In the context of mammary epithelial cells,
Immunohistochemical methods were then used to ana- MTA3 acts to repress genes implicated in dramatic cell
lyze expression of markers of B cell and plasma cell fate alterations. The finding that MTA3 and the Mi-2/
differentiation. The mature B cell marker CD20 was ro- NuRD complex regulate cell fate in two biologically di-
bustly expressed in the CD19-positive population (Fig- verse models suggests that an important conserved
ures 7A and 7B). The plasma cell-selective marker Syn- function of this corepressor complex is repression of
decan-1 (CD138) was expressed to a significantly higher master regulatory genes integral to cell fate changes
extent in the CD19-negative population (Figures 7C and during development and differentiation. This prediction
7D). In addition, the CD19-negative cells displayed ro- highlights the importance of cell type specificity of co-
bust cytoplasmic staining for the Kappa immunoglobulin activators and corepressors, suggesting that alterations
light chain, whereas the CD19-positive cells exhibited in the subunit composition of these transcriptional regu-
scant cytoplasmic staining with occasional cell surface latory complexes may be integral to the establishment
expression, as expected (Figures 7E and 7F). Thus, tran- of cell type-specific transcriptional programs.
sient expression of BCL-6 and MTA3 in a plasma cell The simplest example of this prediction has been ob-
line was sufficient to not only alter its transcriptional served if one follows the role of CIITA. CIITA is the
program toward that of a B lymphocyte but also to alter limiting factor governing whether a cell expresses MHC
the pattern of protein synthesis reflective of a reversion class II genes as well as the antigen presentation acces-
in cell fate. sory genes, invariant chain, HLA-DM, and HLA-DO (Boss
and Jensen, 2003). During B cell development, MHC
Discussion class II expression occurs in the pro-B cell stage, in-
creases during B cell maturation, but is extinguished in
Our results identify a molecule involved in transcriptional terminally differentiated plasma cells. Blimp-1 has been
regulation during the B lymphocyte developmental pro- shown to mediate the silencing of MHC class II genes
gram. MTA3 expression mirrors that of BCL-6 in cells through the repression of CIITA expression (Piskurich
of the B lymphocyte lineage and molecular analysis re- et al., 2000). The interaction of Blimp-1 with promoter III
of the CIITA gene is consistent with the findings reportedveals a functional role in B cell-specific transcription.
MTA3 in B Cell Development
83
here and supports the model that MTA3 and BCL-6 marks in terminally differentiated cells and more labile
regulate MHC class II expression by repressing the ex- modifications in intermediate cell types.
pression of Blimp-1. Preliminary studies suggest that
Experimental Proceduresspecific histone modifications associated with gene ex-
pression are lost during the B cell, plasma cell transition
Cell Culture, Transfection, and Adenovirus Infection
and it is likely that Blimp-1 mediates these events. Lymphocyte and plasma cell lines were cultured in RPMI (Cellgro),
The differentiation program of B lymphocytes is regu- and HeLa and 293T cells were cultured in DMEM with 10% (v/v) fetal
lated, in part, by a negative feedback mechanism involv- bovine serum (Gibco). Cells were transfected with Lipofectamine
(Invitrogen) or Fugene 6 (Roche). Adenovirus carrying human MTA3ing the transcriptional repressors BCL-6 and Blimp-1
and human BCL6 was prepared as described (He et al., 1998). The(Lin et al., 2003; Shaffer et al., 2002b; Shapiro-Shelef et
virus was purified by CsCl banding with 1011 to 1012 plaque-formingal., 2003). These transcription factors exhibit mutually
units and introduced into cells. Luciferase activities were deter-exclusive patterns of expression and definition of the
mined as described (Fujita et al., 2003). Values are the means and
transcriptional programs downstream of their function standard deviations of the results from three independent experi-
supports the notion that these repressors are master ments.
regulators of B lymphocyte and plasma cell identity
Plasmids(Shaffer et al., 2000, 2002a). In fact, targeted disruption
Expression vectors were constructed by subcloning BCL6 cDNAof Blimp-1 in the lymphocyte lineage leads to a failure
(kind gift of Ricardo Dalla-Favera) into pCDNA3 (Invitrogen) andto produce plasma cells (Shapiro-Shelef et al., 2003).
pCMV-Gal4 (pcDNA3-BCL6 and pCMV-Gal4-BCL6). pcDNA3-MTA3Likewise, inappropriate expression of BCL-6 following
was described (Fujita et al., 2003). The fragment containing five Gal4
translocation is believed to contribute to lymphomagen- binding sites was inserted into the TK-promoter-containing pGL2-
esis, at least in part by maintaining repression of Blimp-1 Basic vector (Promega). The promoter regions of human CCL3 were
(Shaffer et al., 2002b). Feedback between transcriptional amplified from human genomic DNA and cloned into pGL2-Basic.
Primers for CCL3 promoter amplification are as follows:repressors is an evolutionarily ancient strategy to pro-
5-GGTACCTAGAGTTATAAACGATGCTG-3duce stable patterns of gene expression (Monod and
5-AAGCTTGGGCTCGAGTGTCAGGAGAG-3Jacob, 1961). The molecular details of transcriptional
The 1 (5–129 aa), 2 (141–706 aa), 3 (141–706 aa), 4 (1–507
repression utilized in such systems differ, but the funda- aa), and 4 (141–507 aa) of BCL6 cDNA were subcloned into pCMV-
mental strategy remains the same. Gal4. The mutants of BCL6 (KKYR, QQYQ) were generated by muta-
The molecular mechanisms utilized by Blimp-1 and genesis using the QuickChange site-directed mutagenesis kit (Stra-
tagene).BCL-6 provide interesting insights into cell type-specific
patterns of transcription during eukaryotic development
Antibodies and Western Blottingand differentiation. Recent evidence has shown that
Antibodies against MTA3, MTA2, Mi2, and MBD3 were previouslyBlimp-1 (PRD-BF1) interacts with the histone methyl-
described (Fujita et al., 2003). Anti-NCoR and -SMRT polyclonal
transferase G9a (Gyory et al., 2004), which has been antibodies were the kind gift of Jiemin Wong. Other antibodies uti-
shown to mediate methylation of lysine 9 of histone H3 lized were anti-HDAC1 and anti-HDAC2 (Santa Cruz), anti-BCL6
(H3K9), leading to a repressive state (Tachibana et al., (DAKO), anti-GFP (ZYMED), anti--actin (Chemicon), anti-HA
(Roche), anti-FLAG (M2), and anti-FLAG (M5) (Sigma).2001). The utilization of lysine methylation as an epige-
netic mark by a master regulator of the plasma cell
Construction of Recombinant Proteintranscriptional program raises an interesting concept.
The1 (1–147 aa),2 (148–265 aa),3 (266–378 aa), and4 (379–515During differentiation, cell type changes progress from a
aa) of MTA3 cDNA and the 1 (5–129 aa), 3 (519–706 aa), and
state of pluripotency to one of restricted developmental 5 (141–507 aa) of BCL6 cDNA were subcloned into pGEX-4T-1
potential. Concurrent with these alterations in cell physi- (Amersham Pharmacia). The 5 (141–507 aa) of BCL6 cDNA was
ology are epigenetic alterations that contribute to cell subcloned into pRSET (Invitrogen). GST or His fusion proteins were
expressed in E. coli BL21(DE3) and were purified by glutathione-type-specific transcriptional patterns. The example of
agarose (sigma) or Probond resin (Promega).B lymphocyte development and ultimate terminal differ-
entiation into plasma cells highlights this phenomenon.
GST Pull-Down AssayIn the germinal center B lymphocyte, a cell that must
Bacterially expressed GST and GST-fused proteins (2 g) were im-
rapidly respond to environmental cues, a master tran- mobilized on glutathione-agarose beads and incubated with either
scriptional regulator, BCL-6, utilizes an epigenetic modi- whole lysates from Raji cells or His-tagged proteins (1 g) in a buffer
fication, lysine acetylation, that is freely and rapidly re- (250 l) containing 0.1% TritonX-100, 50 mM HEPES, pH 7.4, 100
or 400 mM NaCl, 5% glycerol, 2 mM DTT, 0.1 mg/ml BSA andversible. In contrast, a terminally differentiated version
protease inhibitors for 1 hr at 4C.of the germinal center B lymphocyte, the plasma cell,
is less responsive to external stimuli and exhibits re-
Immunoprecipitationstricted capacity to alter its transcriptional program. The
Cells were lysed with hypotonic buffer: 0.5% Triton X-100, 10 mM
primary epigenetic mark deposited by a master regula- Tris (pH 7.5), 10 mM NaCl, 3 mM MgCl2, 0.2 mM PMSF, and 1 mM
tor of the plasma cell program, Blimp-1, is lysine methyl- dithiothreitol (DTT). After centrifugation at 4000 rpm for 2 min, nu-
ation, a mark with considerably greater chemical and clear pellets were extracted with 10 mM Tris (pH 7.5), 500 mM NaCl,
biological stability than lysine acetylation. Thus, in this 3 mM MgCl2, 10% glycerol, 1% CHAPS, 0.2 mM PMSF, and 1 mM
DTT. After centrifugation, the supernatants were dialyzed versus 10example, a terminally differentiated cell utilizes a chemi-
mM Tris (pH 7.5), 100 mM NaCl, 1 mM MgCl2, 20% glycerol, 0.2 mMcally more stable epigenetic mark in establishment of a
PMSF, and 1 mM DTT. Aliquots of nuclear extract (200–400 g) werecell type-specific transcriptional program than does an
incubated with specific antibodies or with control IgG (Santa Cruz)
intermediate cell type in the differentiation pathway. We for 1 hr at 4C followed by incubation for 1 hr with 25 l of protein
propose that one strategy to restrict plasticity of cell G/A agarose (Oncogene).
type-specific transcriptional programs involves utiliza- The detection of protein-protein interactions in Ramos or Raji
cells was described (Bereshchenko et al., 2002). Briefly, we treatedtion of chemically and biologically stable epigenetic
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Ramos cells with 5 mM NIA and/or 1 M Trichostatin A (TSA) for the CMV promoter used for protein expression had been deleted.
All other adenovirus manipulations were performed as described5 hr. Cells were lysed with hypotonic buffer with 5 mM NIA and/or
1 M TSA (sigma). After centrifugation, nuclear pellets were ex- for overexpression.
tracted with 20 mM HEPES (pH 7.9), 500 mM KCl, 0.2 mM EDTA
(pH 8.0), 2 mM EGTA (pH 8.0), 0.75 mM spermidine, 0.15 mM sperm- Immunohistochemistry
ine, 25% glycerol, 0.2 mM PMSF, 2 mM DTT, 10 mM NIA, and/ Formalin-fixed paraffin-embedded (FFPE) tissue sections were ob-
or 50 M TSA (sigma). After centrifugation, the supernatants were tained from the archives of the Emory University Division of Ana-
dialyzed versus 20 mM HEPES (pH 7.9), 100 mM KCl, 0.2 mM EDTA tomic Pathology. FFPE sections of tissue culture cell pellets were
(pH 8.0), 0.2 mM EGTA (pH 8.0), 20% glycerol, 0.2 mM PMSF, 2 mM prepared after selection with CD19-microbeads on a MACS column
DTT, 10 mM NIA and/or 10 M TSA (sigma), and/or 5 mM sodium (Millenyi Biotech). Sections of 4 m thickness on glass slides under-
n-Butyrate. Aliquots of nuclear extracts (200–400 g) were incu- went standard deparaffinization and rehydration (Jaye et al., 2003).
bated with specific antibodies for 1 hr at 4C followed by incubation Antigen unmasking and staining of tissue sections with polyclonal
for 1 hr with 25 l of protein G/A agarose. anti-MTA3 antibody was performed as described previously (Fujita
et al., 2003). Antigen unmasking and staining of cell pellets with
antibodies to CD20, CD138, and kappa and lambda immunoglobulinRNA Extraction and RT-PCR
light chains (DAKO) were performed according to manufacturer’sTotal RNA was extracted by a modified guanidium thiocyanate-
instructions. Detection with the LSAB2 System (DAKO) for immuno-phenol-chloroform extraction as described (Fujita et al., 2003). cDNA
peroxidase staining followed the manufacturer’s recommendations.was synthesized with M-MLV reverse transcriptase (Life Technolo-
Following diaminobenzidine (DAB) exposure, sections were coun-gies) using random hexamers as described (Fujita et al., 2003). The
terstained with hematoxylin before mounting for light microscopycDNA was amplified using the following primers:
and photography.Blimp1: 5-ACTTGCAACAAGGGCTTTAc-3; 5-ACCTTGCATTGG
TATGGTTT-3
Immunofluorescence MicroscopyCCL3: 5-GCAACCAGTTCTCTGCATCA-3; 5-ACTCCTCACTGG
Cryostat sections were cut to 8 m thickness, placed on glassGGTCAGC-3
slides, and fixed and permeablized for 10 min at room temperature-actin: 5-CTCTTCCAGCCTTCCTTCCT-3; 5-AGCACTGTGTTG
with ice-cold PBS, 3.7% paraformaldehyde, 0.5% Triton X-100. AfterGCGTACAG-3
three washes with PBS, sections were blocked for 30 min at roomCIITA (total): 5-CTGAAGGATGGTGGAAGACCTGGGAAAGC-3;
temperature with PBS, 3% BSA. Sections were stained for 1 hr at5-GTGCCCGATCTTGTTCTCACTC-3
room temperature with primary antibody cocktail (mouse anti-Bcl-6CIITA (pI): 5-GGAGACCTGGATTTGGCCCT-3; 5-GAAGCTCCA
[Dako, Carpinteria, California] at 1:10 and rabbit anti-MTA3 at 1:200)GGTAGCCACCTTCTA-3
and washed with PBS. Bound primary was detected with secondaryCIITA (pIII): 5-GGGGAAGCTGAGGGCACG-3; 5-GAAGCTCCAG
reagent cocktail composed of Alexa-568-goat-anti-rabbit IgG (H &GTAGCCACCTTCTA-3
L) and Alexa-488 donkey anti-mouse IgG (H & L; Molecular Probes,CIITA (pIV): 5-GCGGCCCCAGAGCTGG-3; 5-GAAGCTCCAGGT
Eugene, Oregon), each at 1:1000. After washing with PBS, nucleiAGCCACCTTCTA-3
were stained with To-pro-3-iodide (Molecular Probes) at 1:1000 inGAPDH: 5-CCATGGGAGGTGAAGGTCGGAGTC-3; 5-GGTGGT
PBS for 2 min. After washing, sections were mounted and coverGCAGGAGGCATTGCTGATG-3
slipped for confocal microscopy as described (Ivanov et al., 2004).XBP-1: 5-TCTGGCGGTATTGACTCTTC-3; 5-GAGAAAGGGAG
GCTGGTAAG-3
Syndecan-1: 5-GAGCAGGACTTCACCTTTGA-3; 5-TTCGTCCT Flow Cytometry
TCTTCTTCATGC-3 Cells were harvested on day 6 or day 7 following adenoviral infection
SYK: 5-AGATCTGGCTGCAAGAAATG-3; 5-ATGCTTCCCACAT and brought to 1  106 to 5  106 cells in 100 l in PBS, 0.5% BSA.
CAACACT-3 Cell suspensions were incubated for 20 min with 5 l of peridinin
BLNK: 5-CCTGTGATCGAAAGTCTGCT-3; 5-TTGCTTCAATAAA chlorophyll protein (Per-CP)-anti-HLA-DR and allophycocyanin
TCGCACA-3 (APC)-conjugated anti-CD19 monoclonal antibodies or isotype con-
Ig-: 5-TTCTGTCAGCAGAAGTGCAA-3; 5-GGAAGATAGGCAC trols (BD Biosciences, San Jose, California). After washing, cells
GATGATG-3 were fixed with 1.8% paraformaldehyde for 10 min and washed
Amplification of CIITA followed previously described conditions once with PBS, 0.5% BSA. Cells were analyzed on a FACSCaliber
(Nagarajan et al., 2002). cytometer (Becton Dickinson, San Jose, California), and data were
acquired and analyzed as described (Jaye et al., 2001).
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